Kala Bio Q2 net loss narrows to $1.58 million from year-ago $11.16 million

Shift toward an on-premises AI platform-as-a-service model continues, with development centered on the licensed Researgency agentic AI platform.

Kala Bio posted a quarterly net loss of $1.58 million, narrowing from $11.16 million a year earlier.

Total operating expenses fell to $1.72 million from $11.03 million, led by research and development spending dropping to $59,000 from $6.23 million.

General and administrative expense declined to $1.66 million from $4.64 million, reflecting lower employee-related and stock-based compensation costs.

Interest expense was nil versus $1.08 million, with no indebtedness outstanding under the Oxford Finance loan agreement.